Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032161 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tim Altendorf und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Biologische Informationsprozesse, IBI-7, Forschungszentrum Jülich, 52425 Jülich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Tauopathies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease and other tauopathies are the world’s leading causes of dementia and memory loss. These diseases are thought to be caused by the misfolding and aggregation of the intracellular tau protein, ultimately leading to neurodegeneration. The tau protein is involved in a multitude of different neurodegenerative diseases. During the onset of tauopathies, tau undergoes structural changes and posttranslational modifications and aggregates into amyloid fibrils that are able to spread with a prion-like behavior. Up to now, there is no therapeutic agent which effectively controls or reverses the disease. Most of the therapeutics that were developed and underwent clinical trials targeted misfolded or aggregated forms of tau. In the current manuscript, we present the selection and characterization of two all D-enantiomeric peptides that bind monomeric tau protein with a low nanomolar KD, stabilize tau in its monomeric intrinsically disordered conformation, and stop the conversion of monomers into aggregates. We show that the effect of the two all D-enantiomeric peptides is strong enough to stop ongoing tau aggregation in vitro and is able to significantly reduce tau fibril assembly in cell culture. Both compounds may serve as new lead components for the development of therapeutic agents against Alzheimer’s disease and other tauopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Biologische Informationsprozesse, IBI-7, Forschungszentrum Jülich, 52425 Jülich, Germany.
- Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany.
- Zentralinstitut für Engineering, Elektronik und Analytik, ZEA-3, Forschungszentrum Jülich, 52425 Jülich, Germany.
ORCID-Profile: Ian Gering, Beatrix Santiago-Schübel, Gültekin Tamgüney, Markus Tusche, Jeannine Mohrlüder, Dieter Willbold
Zitieren
APA
Altendorf, T., Gering, I., Santiago-Schübel, B., Aghabashlou Saisan, S., Tamgüney, G., Tusche, M., Honold, D., Schemmert, S., Hoyer, W., Mohrlüder, J., & Willbold, D. (2023). Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032161
Vancouver
Altendorf T, Gering I, Santiago-Schübel B, Aghabashlou Saisan S, Tamgüney G, Tusche M, et al. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032161
BibTeX
@article{Altendorf2023,
author = {Altendorf, Tim and Gering, Ian and Santiago-Schübel, Beatrix and Aghabashlou Saisan, Selma and Tamgüney, Gültekin and Tusche, Markus and Honold, Dominik and Schemmert, Sarah and Hoyer, Wolfgang and Mohrlüder, Jeannine and Willbold, Dieter},
title = {Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032161}
}
EUVIMED